Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ORGANIZATION
ORGANIZATION
- Realistic Approach Should Be Taken for Supply Chain Surveys: JPMA Economic Security Taskforce
March 15, 2022
- Japan Drug Makers Launch Digital Health Advocacy Group, Mitsubishi Tanabe Exec Serves as Head
March 15, 2022
- Switch to Original Drugs Up Nearly 5-Fold YOY in 6-Month Period from August 2021: NPhA Survey
March 15, 2022
- API Import Costs from Europe Surging amid Russian Airspace Closures
March 15, 2022
- List of 180 Needed Drugs Compiled in Europe-Led Drive to Support Ukraine
March 14, 2022
- Therapeutic Value of Kampo Medicines for COVID-19 Being Examined
March 11, 2022
- Generic/Biosimilar Association Proposes Establishing Inspector Database to Stem GMP Violations
March 9, 2022
- Apply Only Market Price-Linked Rules in Next Off-Year Revision, No Hasty Debate for Adjustment Rate: JMA Official
March 8, 2022
- Antimicrobial Use Fell 30-40% Between January 2019 and January 2021: JPA
March 7, 2022
- JMA Calls for Investigation into Increasing Cases of Off-Label Use of GLP-1 Agents
March 4, 2022
- FPMAJ Starts Survey on Industry’s Inspection Status for “Stable Supply Medicines”
March 3, 2022
- JPMA, Overseas Pharma Groups Call for Improvements in Access to COVID-19 Vaccines
March 1, 2022
- Impact of Ukraine Invasion Limited in Japan? Trader Group Says Epirubicin Is Only API Possibly Affected
February 25, 2022
- FPMAJ Begins Survey on Lifting of Shipment Restrictions
February 24, 2022
- Chuikyo Payer Rep Wants Category-Based Debate on Adjustment Rate, Prods PMP Cuts in Next Off-Year Revision
February 24, 2022
- Takeda’s Ramona Sequeira Becomes 1st Female PhRMA Chair
February 15, 2022
- Govt-Industry Arrangement for Drug Supply Survey Hits Rough Waters; FPMAJ Stands Pat on Continued Dialogue
February 10, 2022
- PhRMA Taps Diplomat Hans Klemm as New Japan Representative
February 3, 2022
- Japan Market Should Grow in Single-Digit Range, Not Zero Growth: PhRMA Chair
January 31, 2022
- JPMA Embarking on Holistic Social Security Debate, Health Coverage Review: Chief
January 21, 2022
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…